Research Analysts Set Expectations for EVAX FY2025 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Investment analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Evaxion Biotech A/S in a research note issued on Wednesday, April 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.03) per share for the year, down from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2026 earnings at ($0.02) EPS.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.19. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.66 million.

Separately, Lake Street Capital reduced their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Price Performance

Shares of EVAX stock opened at $1.38 on Monday. The company has a market capitalization of $1.62 million, a P/E ratio of -0.95 and a beta of -0.25. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 12 month low of $1.36 and a 12 month high of $22.05. The stock has a 50 day moving average of $2.10 and a two-hundred day moving average of $6.45.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC lifted its stake in Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,400 shares of the company’s stock after buying an additional 7,200 shares during the period. Invst LLC owned about 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.